Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Eyelid Cancer

This section has been reviewed and approved by the Cancer.Net Editorial Board, 5/2012
After Treatment

After treatment for eyelid cancer ends, talk with your doctor about developing a follow-up care plan. This plan may include regular physical examinations and/or medical tests to monitor your recovery for the coming months and years. ASCO offers cancer treatment summary forms to help keep track of the cancer treatment you received and develop a survivorship care plan once treatment is completed. Most patients treated for eyelid cancer are successfully treated with a good cosmetic result.

Most people do not have any long-term effects because of the cancer. However, people treated for eyelid cancer need close observation by their ophthalmologist and oncologist to ensure that the tumor does not recur or spread to other organ systems. The doctor will make specific recommendations regarding the frequency of necessary follow-up examinations for you. In some circumstances, your doctor may also recommend routine blood and imaging testing to ensure that there is no recurrence or spread of the tumor.

Some side effects may occur months or years after treatment, called late effects, and therefore continued follow-up care by your doctor is very important.

People recovering from eyelid cancer are encouraged to follow established guidelines for good health, such as maintaining a healthy weight, not smoking, eating a balanced diet, and having recommended cancer screening tests. Talk with your doctor to develop a plan that is best for your needs. Moderate physical activity can help rebuild your strength and energy level. Your doctor can help you create an appropriate exercise plan based upon your needs, physical abilities, and fitness level. Learn more about the next steps to take in survivorship, including making positive lifestyle changes.

Find out more about common terms used after cancer treatment is complete.

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: